Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Ipsen SA announces positive top line results from phase III clinical study of Decapeptyl


Friday, 7 Feb 2014 01:30am EST 

Ipsen SA:Announced that the phase III clinical trial evaluating Decapeptyl 11.25 mg administered subcutaneously in patients with locally advanced or metastatic prostate cancer has met its primary endpoints.Based on these results, Ipsen intends to apply for the addition of the subcutaneous route, alongside the intramuscular route, to the label of triptorelin pamoate 11.25 mg. 

Company Quote

33.825
0.48 +1.44%
7:04am EDT